Navigation Links
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
Date:2/12/2008

SAN CARLOS, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced a restructuring today designed to complete its transition from a drug delivery service provider to a therapeutics drug development organization. The restructuring will streamline the company, consolidate corporate functions, and strengthen decision-making and execution within the business units.

"We are transforming Nektar into a world-class drug development company and these changes are a natural progression on the path to achieving this vision," said Howard W. Robin, President and Chief Executive Officer of Nektar. "This restructuring aligns the organization with the future direction of our company and strengthens our ability to drive programs rapidly through the clinic."

Approximately 150 positions have been eliminated as a result of the restructuring. Importantly, Nektar has preserved the necessary technical and manufacturing personnel and capabilities to support its ongoing effort to forge a new partnership for its inhaled insulin programs.

Nektar has made significant progress this past year in advancing its proprietary pipeline. The company recently initiated phase 2 clinical trials for its two leading PEGylated small molecule programs, NKTR-102 (PEG-irinotecan) for solid tumors and NKTR-118 (oral PEG-naloxol) for opioid bowel dysfunction. NKTR-061 (inhaled amikacin), which is being co-developed with Bayer AG to treat hospital-acquired pneumonia, is expected to enter Phase 3 trials this year.

The company will release its full financial results for the fourth quarter and full year 2007 on February 27, 2008. At that time, it will host a conference call for investors and analysts beginning at 2:00 PM PT/5:00 PM
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
2. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
3. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
4. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
5. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. PAREXEL International Announces 2-For-1 Stock Split
10. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Automotive, a group of car dealerships headquartered in ... Center and offering free oil change coupons for participation in ... 18 at the Bill Jacobs Cadillac and Chevrolet location from ... )  The Bill Jacobs Auto annual blood ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... its information, which is why content management software can ... organization really need? , ,Implementing a content management system ... operating costs, shorter publishing deadlines, greater efficiency and a ... with nearly 1,000 CMS solutions to choose from, identifying ...
... the only one completely confused by the Cingular merger with ... facts of the deal. Cingular Wireless acquires the assets and ... have 46 million customers, topping now No. 2 carrier Verizon ... keeps the rights to the AT&T Wireless brand and plans ...
... 4,000 employees worldwide. Headquartered in Carlsbad, California. , Dynal ... in Brown Deer. Headquartered in Oslo, Norway. Brown ... plans to acquire Dynal Biotech ASA , whose ... the end of March for $380.4 million. , ...
Cached Biology Technology:Consider the content when managing information online 2Consider the content when managing information online 3Consider the content when managing information online 4Cingular confusion 2Cingular confusion 3Invitrogen to buy Norwegian biotech with operations in Brown Deer 2
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
(Date:4/17/2014)... -- Indiana University researchers have detected new early-warning signs ... This discovery could have far-reaching implications for the diagnosis ... of over 25 million Americans. , "We had not ... at such early stages," said Ann Elsner, professor and ... lead author of the study. "We set out to ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... University professor is trying to create a patient-friendly treatment ... diagnosed with lung cancer each year., Masaaki Tamura, associate ... are working on several projects that use nanoparticles to ... estimated that nearly 156,940 people will die from lung-related ...
... brain cancer will benefit from the results of a ... of targeted gene therapies and improve prognosis. ... microRNAs on glioblastoma multiforme, a deadly brain cancer, by ... genes associated with different stages of cancer development and ...
... millipedes usually have one or two pairs of legs ... specialized gonopods are used as claspers to hold the ... published in BioMed Central,s open access journal Frontiers ... development and the internal reorganization needed to produce functional ...
Cached Biology News:Targeting a cure: Research looks at developing a bull's-eye therapy to combat lung cancer 2Targeting a cure: Research looks at developing a bull's-eye therapy to combat lung cancer 3Small molecules shed light on cancer therapies 2The secret life of millipedes 2
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
Recombinant Human HGF...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: